Stock SQURPHARMA SQUARE PHARMACEUTICALS PLC.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Square Pharmaceuticals PLC.

Equities

SQURPHARMA

BD0473SQPH00

End-of-day quote Dhaka S.E.
Other stock markets
 06:00:00 2024-04-29 pm EDT 		5-day change 1st Jan Change
210.9 BDT +1.39% Intraday chart for Square Pharmaceuticals PLC. -0.85% +0.29%
Apr. 30 Square Pharmaceuticals PLC. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2024 CI
Feb. 01 Square Pharmaceuticals PLC. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023 CI

Strengths

  • The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
  • The group's activity appears highly profitable thanks to its outperforming net margins.
  • Its low valuation, with P/E ratio at 8.82 and 7.58 for the ongoing fiscal year and 2025 respectively, makes the stock pretty attractive with regard to earnings multiples.
  • The company is one of the best yield companies with high dividend expectations.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
  • Considering the small differences between the analysts' various estimates, the group's business visibility is good.
  • Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.

Weaknesses

  • The company's earnings releases usually do not meet expectations.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
SQUARE PHARMACEUTICALS PLC. Stock Square Pharmaceuticals PLC.
+0.29% 1.7B -
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+29.68% 681B
C+
NOVO NORDISK A/S Stock Novo Nordisk A/S
+25.07% 556B
B
JOHNSON & JOHNSON Stock Johnson & Johnson
-4.35% 361B
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+17.65% 325B
B-
ABBVIE INC. Stock AbbVie Inc.
+3.77% 285B
C+
ASTRAZENECA PLC Stock AstraZeneca PLC
+14.68% 235B
B+
NOVARTIS AG Stock Novartis AG
+4.71% 199B
B-
ROCHE HOLDING AG Stock Roche Holding AG
-12.43% 189B
A+
PFIZER, INC. Stock Pfizer, Inc.
-3.79% 157B
C+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
-

Valuation

P/E ratio
EV / Sales
-
Price to Book
Price to Free Cash Flow
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
  1. Stock Market
  2. Equities
  3. SQURPHARMA Stock
  4. Ratings Square Pharmaceuticals PLC.